IGF2BP1-m6A-THBS1 Axis Drives Macrophage Polarization in Pulmonary Fibrosis

Study Background and Research Question

Pulmonary fibrosis (PF) is a progressive, often fatal disease characterized by excessive extracellular matrix deposition, fibroblast accumulation, and chronic inflammation. While the etiology of idiopathic pulmonary fibrosis (IPF) remains incompletely understood, growing evidence implicates metabolic dysregulation and immune cell plasticity—particularly the dichotomous roles of macrophages—in disease pathogenesis (reference). Classically activated (M1) macrophages drive inflammation, whereas alternatively activated (M2) macrophages promote tissue remodeling and fibrosis. Despite recognition of these phenotypes, the molecular mechanisms orchestrating macrophage polarization and metabolic reprogramming in PF are only partially defined. Recent studies suggest that N6-methyladenosine (m6A) RNA modification dynamically regulates gene expression and cellular function in fibrotic diseases. The role of m6A readers, especially IGF2BP1, in modulating macrophage behavior and metabolic adaptation in PF has not been fully elucidated. This study addresses the question: How does IGF2BP1, through m6A-mediated stabilization of target mRNAs, influence macrophage phenotype and metabolism to drive pulmonary fibrosis progression?

Key Innovation from the Reference Study

The principal innovation of Hu et al. (2025) is the identification of a novel IGF2BP1/THBS1/TLR4 regulatory axis in pulmonary fibrosis (reference). The study demonstrates that IGF2BP1, an m6A-binding protein, is overexpressed in macrophages during bleomycin-induced PF. It facilitates fibrotic progression by stabilizing thrombospondin-1 (THBS1) mRNA in an m6A-dependent manner, which in turn activates TLR4 signaling. This axis promotes M2 macrophage polarization and enhances glycolytic metabolism—a metabolic phenotype previously associated with fibrogenesis. By dissecting these interactions, the study links posttranscriptional modification to immunometabolic reprogramming in the fibrotic lung.

Methods and Experimental Design Insights

The authors employed a multi-tiered experimental approach:

• In vivo: Pulmonary fibrosis was induced in mice via intratracheal bleomycin administration. IGF2BP1 expression was manipulated using genetic knockdown strategies.
• Histopathology and Biochemical Assays: Lung fibrosis was quantified via Ashcroft scores, hydroxyproline content, and immunohistochemistry for fibrosis markers (TGF-β1, α-SMA, Collagen-I/III).
• Macrophage Phenotyping: Flow cytometry and immunostaining assessed proportions of CD68+/CD163+ (M2) and other macrophage markers. Gene expression of cytokines (IL-6, IL-1β), matrix regulators (TIMP1), and M2 markers (Arg1, CCL18, Ym1) was measured by qPCR and ELISA.
• Mechanistic Studies: RNA immunoprecipitation, mRNA stability assays, and m6A mapping characterized IGF2BP1-THBS1 interactions. Rescue experiments involved overexpression or knockdown of THBS1 and TLR4 in vitro.
• Metabolic Analysis: Glycolysis in macrophages was evaluated by measuring HK2, LDHA, and PKM2 expression, as well as lactate, glucose uptake, and ATP production.

This multi-modal approach combined in vivo relevance with mechanistic dissection, reinforcing the causative link between IGF2BP1, m6A modification, macrophage polarization, and fibrotic outcomes (reference).

Protocol Parameters

• Assay: Bleomycin-induced pulmonary fibrosis model | Value: 1.5–2 mg/kg bleomycin (mouse) | Applicability: In vivo fibrosis induction | Rationale: Standard for recapitulating PF pathology | source: paper
• Assay: Macrophage polarization quantification | Value: CD68+/CD163+ FACS analysis | Applicability: Evaluating M2 phenotype proportion in lung tissue | Rationale: Distinguishing functional macrophage subsets | source: paper
• Assay: Glycolytic enzyme expression (HK2, LDHA, PKM2) | Value: Relative mRNA/protein quantification | Applicability: Assessing glycolytic reprogramming in macrophages | Rationale: Links metabolic state to fibrotic activity | source: paper
• Assay: M-CSF-dependent macrophage culture | Value: 10–50 ng/mL (typical for in vitro differentiation) | Applicability: Generating and sustaining primary mouse macrophages | Rationale: Ensures proliferation and functional polarization | source: workflow_recommendation

Core Findings and Why They Matter

Key findings from the study include:

• IGF2BP1 is upregulated in macrophages during PF. Its knockdown attenuates fibrosis, reducing inflammatory infiltration, fibroblast proliferation, and matrix deposition (reference).
• IGF2BP1 stabilizes THBS1 mRNA in an m6A-dependent manner, directly enhancing THBS1 protein levels in macrophages. This stabilization is essential for sustaining the fibrotic M2 phenotype.
• THBS1 overexpression rescues suppressed M2 polarization and glycolytic activity in IGF2BP1-deficient macrophages, as evidenced by restoration of HK2, LDHA, PKM2, and metabolic flux parameters.
• THBS1 interacts with TLR4, and TLR4 overexpression reverses the inhibitory effect of THBS1 knockdown on macrophage M2 polarization and glycolytic reprogramming. This confirms that the IGF2BP1/THBS1/TLR4 axis is functionally upstream of these processes.

The study provides robust evidence that m6A-mediated posttranscriptional regulation orchestrates both the immunological and metabolic rewiring of macrophages in the fibrotic lung. These insights are significant for researchers investigating the molecular underpinnings of PF and those developing targeted therapies focused on the macrophage compartment.

Comparison with Existing Internal Articles

Internal resources such as "Recombinant Mouse M-CSF: New Insights into Macrophage Regulation" and "Optimizing Macrophage Assays with Recombinant Mouse Macro..." provide practical guidance on in vitro macrophage differentiation, survival, and proliferation using Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF). These resources emphasize the importance of using well-characterized M-CSF sources to maintain cell viability and reproducibility in assays involving macrophage activation and cytokine release or studies of osteoclast progenitor proliferation. While they focus on assay optimization and best practices, the reference study extends this foundation by elucidating how epigenetic and metabolic programs—rather than exogenous growth factors alone—shape macrophage behavior in a disease-relevant context. Thus, the reference paper’s mechanistic insights can inform experimental design and interpretation in studies leveraging recombinant cytokines for macrophage research.

Limitations and Transferability

While the study’s findings are well-supported by murine models and in vitro systems, several limitations warrant consideration:

• Species specificity: Mouse models recapitulate many but not all aspects of human PF; the transferability of the IGF2BP1/THBS1/TLR4 axis to human disease requires further validation (reference).
• Complexity of macrophage heterogeneity: While M2 polarization is central to the study, macrophage phenotypes in vivo are dynamic and influenced by multiple cues beyond those investigated here.
• Therapeutic translation: The direct targeting of IGF2BP1 or m6A readers in clinical settings is still in early development, and off-target or compensatory effects remain possible.
• Metabolic modulation: Although glycolytic reprogramming is implicated, other metabolic pathways (e.g., fatty acid oxidation) may also contribute to macrophage-mediated fibrogenesis but were not addressed in detail.

Nevertheless, the work supplies a solid mechanistic framework and testable hypotheses for future translational research.

Research Support Resources

For researchers seeking to model macrophage-driven fibrotic processes or perform macrophage proliferation assay reagent workflows, validated reagents such as Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag (SKU PM2021) can support reliable in vitro differentiation and activation of mouse macrophages (source: workflow_recommendation). These experimental foundations are critical for reproducing and extending mechanistic studies, including those examining macrophage activation, cytokine release, and metabolic responses in fibrotic disease models. For protocol optimization, see scenario-based guidance in internal articles referenced above. APExBIO provides batch-tested cytokines suitable for advanced immunology and fibrosis research workflows.